These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

711 related articles for article (PubMed ID: 30918109)

  • 21. A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist.
    Abraham J; Bakke S; Rutt A; Meadows B; Merino M; Alexander R; Schrump D; Bartlett D; Choyke P; Robey R; Hung E; Steinberg SM; Bates S; Fojo T
    Cancer; 2002 May; 94(9):2333-43. PubMed ID: 12015757
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preclinical progress and first translational steps for a liposomal chemotherapy protocol against adrenocortical carcinoma.
    Jung S; Nagy Z; Fassnacht M; Zambetti G; Weiss M; Reincke M; Igaz P; Beuschlein F; Hantel C
    Endocr Relat Cancer; 2016 Oct; 23(10):825-37. PubMed ID: 27550961
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current Status and Future Targeted Therapy in Adrenocortical Cancer.
    Alyateem G; Nilubol N
    Front Endocrinol (Lausanne); 2021; 12():613248. PubMed ID: 33732213
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mitotane enhances doxorubicin cytotoxic activity by inhibiting P-gp in human adrenocortical carcinoma cells.
    Gagliano T; Gentilin E; Benfini K; Di Pasquale C; Tassinari M; Falletta S; Feo C; Tagliati F; Uberti ED; Zatelli MC
    Endocrine; 2014 Dec; 47(3):943-51. PubMed ID: 25096913
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adrenocortical Carcinoma: Role of Adjuvant and Neoadjuvant Therapy.
    Kenney L; Hughes M
    Surg Oncol Clin N Am; 2023 Apr; 32(2):279-287. PubMed ID: 36925185
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression profiles analysis identifies the values of carcinogenesis and the prognostic prediction of three genes in adrenocortical carcinoma.
    Gao Z; Man X; Li Z; Bi J; Liu X; Li Z; Zhu Y; Zhang Z; Kong C
    Oncol Rep; 2019 Apr; 41(4):2440-2452. PubMed ID: 30816525
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of adjuvant chemotherapy in patients undergoing curative-intent resection of localized adrenocortical carcinoma.
    Al Asadi A; Hubbs DM; Sweigert PJ; Baker MS; Kabaker AS
    Am J Surg; 2021 Jul; 222(1):119-125. PubMed ID: 33168156
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multi-Target Approach to Metastatic Adrenal Cell Carcinoma.
    Wahab NA; Zainudin S; AbAziz A; Mustafa N; Sukor N; Kamaruddin NA
    Arch Iran Med; 2016 Sep; 19(9):671-3. PubMed ID: 27631184
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Developing treatment for adrenocortical carcinoma.
    Kerkhofs TM; Ettaieb MH; Hermsen IG; Haak HR
    Endocr Relat Cancer; 2015 Dec; 22(6):R325-38. PubMed ID: 26259571
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Conventional chemotherapy and emerging targeted therapy for advanced adrenocortical carcinoma.
    Xu YZ; Zhu Y
    Anticancer Agents Med Chem; 2013 Feb; 13(2):248-53. PubMed ID: 22934700
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term survival in recurrent adrenocortical cancer.
    Shuayb M; Das A; Uddin MN
    BMJ Support Palliat Care; 2019 Mar; 9(1):47-50. PubMed ID: 29903850
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnosis, treatment and outcome of adrenocortical cancer.
    Mihai R
    Br J Surg; 2015 Mar; 102(4):291-306. PubMed ID: 25689291
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adrenocortical cancer treatment.
    Patalano A; Brancato V; Mantero F
    Horm Res; 2009 Jan; 71 Suppl 1():99-104. PubMed ID: 19153517
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-Term Survival in a Patient With Metastatic DDR2-Positive Adrenal Cortical Carcinoma.
    Taza F; Chovanec M; Hahn N; Albany C
    Clin Genitourin Cancer; 2017 Oct; 15(5):e893-e895. PubMed ID: 28606737
    [No Abstract]   [Full Text] [Related]  

  • 35. [Adrenocortical carcinoma and its treatment].
    Tupikowski W; Bednarek-Tupikowska G; Florczak A
    Postepy Hig Med Dosw (Online); 2004 Feb; 58():27-36. PubMed ID: 15069374
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sphingosine kinase 1 is overexpressed and promotes adrenocortical carcinoma progression.
    Xu Y; Dong B; Huang J; Kong W; Xue W; Zhu Y; Zhang J; Huang Y
    Oncotarget; 2016 Jan; 7(3):3233-44. PubMed ID: 26673009
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bioinformatic analyses and experimental validation of the role of m6A RNA methylation regulators in progression and prognosis of adrenocortical carcinoma.
    Xu F; Guan Y; Ma Y; Xue L; Zhang P; Yang X; Chong T
    Aging (Albany NY); 2021 Apr; 13(8):11919-11941. PubMed ID: 33952721
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of Pediatric Adrenocortical Carcinoma With Surgery, Retroperitoneal Lymph Node Dissection, and Chemotherapy: The Children's Oncology Group ARAR0332 Protocol.
    Rodriguez-Galindo C; Krailo MD; Pinto EM; Pashankar F; Weldon CB; Huang L; Caran EM; Hicks J; McCarville MB; Malkin D; Wasserman JD; de Oliveira Filho AG; LaQuaglia MP; Ward DA; Zambetti G; Mastellaro MJ; Pappo AS; Ribeiro RC
    J Clin Oncol; 2021 Aug; 39(22):2463-2473. PubMed ID: 33822640
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MDR1 inhibition increases sensitivity to doxorubicin and etoposide in adrenocortical cancer.
    Creemers SG; van Koetsveld PM; De Herder WW; Dogan F; Franssen GJH; Feelders RA; Hofland LJ
    Endocr Relat Cancer; 2019 Mar; 26(3):367-378. PubMed ID: 30650062
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical management of adrenocortical carcinoma.
    Fassnacht M; Allolio B
    Best Pract Res Clin Endocrinol Metab; 2009 Apr; 23(2):273-89. PubMed ID: 19500769
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.